Suzuken Co., Ltd. (TYO:9987)
Japan · Delayed Price · Currency is JPY | Market Cap | 343.80B -8.9% |
| Revenue (ttm) | 2.49T +3.6% |
| Net Income | 38.14B +10.6% |
| EPS | 545.54 +20.0% |
| Shares Out | 67.64M |
| PE Ratio | 9.32 |
| Forward PE | 13.98 |
| Dividend | 120.00 (2.34%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 8,800 |
| Open | 5,044.00 |
| Previous Close | 5,083.00 |
| Day's Range | 4,972.00 - 5,078.00 |
| 52-Week Range | 4,906.00 - 6,668.00 |
| Beta | 0.22 |
| Analysts | Buy |
| Price Target | 6,466.67 (+27.98%) |
| Earnings Date | May 14, 2026 |
About Suzuken
Suzuken Co., Ltd., together with its subsidiaries, primarily engages in the distribution of pharmaceuticals in Japan and internationally. The company operates in four segments: Pharmaceutical Distribution, Healthcare Product Development, Community Healthcare and Nursing Care Support, and Healthcare Related Services. The Pharmaceutical Distribution Business segment purchases ethical drugs, diagnostic agents, medical equipment, medical materials, and medical food products, as well as pharmaceutical and medical equipment manufacturers, and supplie... [Read more]
Financial Performance
In fiscal year 2026, Suzuken's revenue was 2.49 trillion, an increase of 3.61% compared to the previous year's 2.40 trillion. Earnings were 38.14 billion, an increase of 10.55%.
Financial StatementsNews
Suzuken upgraded to Buy from Hold at Jefferies
Jefferies upgraded Suzuken to Buy from Hold with a price target of 5,900 yen, up from 5,200 yen. The analyst expects the company to beat Q1 estimates and for a